Waypoint Capital Partners has solidified its position in the healthcare sector with a significant investment. An affiliate of Waypoint Capital announced on December 20, 2021, the acquisition of a 70% stake in Allergy Partners, the leading U.S. network of allergy and asthma practices specializing in single-specialty care. David Brown will continue to serve as Chief Executive Officer of Allergy Partners, ensuring continuity in leadership as the organization enters this new phase of growth. The financial terms of this strategic transaction remain undisclosed.
Established in 1977 from a single location in Western North Carolina, Allergy Partners has grown into a national platform for allergy and asthma services. The company now boasts 62 practice hubs and a network of 135 physicians extending across 20 states. Through its extensive network, Allergy Partners delivers over 300,000 patient encounters annually, demonstrating its significant reach and impact in the allergy and asthma care landscape.
Waypoint Capital Partners expressed enthusiasm about the acquisition, stating, “Allergy Partners is a distinguished leader in the industry, characterized by a robust culture of growth and innovation. This acquisition presents an exciting opportunity for both Waypoint and Allergy Partners to leverage the existing strong foundation and expand through both organic development and strategic initiatives. Waypoint recognizes the substantial potential within the allergy market and is committed to providing its expertise and investment capital to support the Allergy Partners team. Together, we aim to extend their valuable services to an even greater number of patients throughout the nation.”
David Brown, CEO of Allergy Partners, also commented on the partnership: “We are thrilled to collaborate with Waypoint Capital Partners as Allergy Partners aims to broaden access to our specialized services for a larger patient population nationwide. Our core mission is to spearhead advancements in the delivery of high-quality healthcare for individuals with asthma and allergic diseases. This partnership with Waypoint will be instrumental in furthering our mission as we continue to implement our strategic initiatives, expand our comprehensive care network, and foster ongoing research and innovation within the allergy and asthma care field.”
For this transaction, McDermott Will & Emery served as legal counsel to Waypoint Capital Partners, and SVB Leerink acted as the exclusive financial advisor.
